Cerebrolysin is unique on this list because it is not a single peptide. It is a mixture of low-molecular-weight peptides and amino acids derived from pig brain tissue. That sounds odd, but it has more clinical trial data than any other nootropic: over 150 published studies for stroke, traumatic brain injury, Alzheimer's, and vascular dementia. It is approved and used clinically in over 40 countries. The US never approved it, not because of safety concerns, but because the multi-component nature makes FDA approval harder. The evidence for acute neurological injury (stroke, TBI) is the strongest. For healthy cognition enhancement, the data is thinner.
Cerebrolysin Protocol
Dose: 5-10mL intramuscular daily for clinical indications. 1-5mL for nootropic use. | Frequency: Once daily, 5 days per week | Cycle: 10-20 day cycles, 2-4 times per year (clinical protocol) | Route: IM (clinical) or IV (hospital). Some people use SubQ off-label.
Cerebrolysin comes as a ready-to-inject solution in ampoules (1mL, 5mL, 10mL). No reconstitution. The clinical dose for stroke/TBI is 10-30mL IV. Nootropic community doses are 1-5mL IM.
Cerebrolysin Effects
Neuroprotection (70%). The strongest evidence is for protecting neurons after acute injury (stroke, TBI). Promotes neuronal survival and reduces damage.
Cognitive recovery (60%). Improved cognitive function in stroke and TBI patients in multiple clinical trials.
Neurotrophic support (55%). Contains BDNF-like and NGF-like activity. Supports neuronal growth and repair.
Memory and focus (35%). Some evidence for memory improvement in elderly patients with dementia. Less clear in healthy young adults.
Cerebrolysin Side Effects
Injection-site pain (25%). IM injections of 5-10mL are painful. Split larger volumes across two sites. Inject slowly.
Headache (8%). Mild headache. Usually resolves within a few hours.
Dizziness (5%). Brief lightheadedness. More common with higher doses.
Cerebrolysin Dosing by Use Case
Condition
Dose
Duration
Notes
TBI recovery
10-30mL IV daily (clinical) or 5-10mL IM daily (community)
10-20 day cycles
The strongest evidence base. Multiple RCTs show improved cognitive outcomes in TBI patients. This is clinical territory. Hospital administration for acute TBI. Community protocols use lower IM doses for post-acute recovery.
Stroke recovery
10-30mL IV daily (clinical)
10-20 day cycles, started within days of stroke
Clinical evidence supports use in acute ischemic stroke. Cerebrolysin promotes neuronal survival and reduces infarct size in animal models. Multiple human trials show improved functional outcomes.
Cognitive enhancement (off-label)
1-5mL IM daily
10-20 day cycles, 2-3 times per year
The nootropic community uses lower doses for general cognitive enhancement. The evidence for this is thinner than for neurological injury. BDNF-like and NGF-like activity may support neuroplasticity. Expect subtle improvements in memory and focus.
Cerebrolysin Results Timeline
Day 1-5, Loading: IM injections daily. Some people report increased mental energy and clarity within the first few days. Others notice nothing until the second week.
Day 5-10, Mid-cycle: Cognitive effects become clearer. Improved verbal recall, better focus, faster processing speed reported by community users.
Day 10-20, Full cycle: Peak cognitive and neurotrophic effects. The cycle ends. Benefits may persist for weeks after stopping as the neurotrophic support continues working.
Frequently Asked Questions About Cerebrolysin
What is cerebrolysin?
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from enzymatic digestion of pig brain protein. It contains BDNF-like and NGF-like neurotrophic factors. It is approved in over 40 countries for stroke, TBI, and dementia. It has more clinical trial data (150+ published studies) than any other nootropic peptide. It is not FDA-approved.
What is the best cerebrolysin dosage?
Clinical (stroke/TBI): 10-30mL IV daily for 10-20 days. Nootropic (community): 1-5mL IM daily for 10-20 days, 2-3 cycles per year. Cerebrolysin comes as a pre-mixed solution in ampoules. No reconstitution needed. The IM injection can be painful due to volume. Split larger doses across two injection sites.
What are the side effects of cerebrolysin?
Injection-site pain (common with IM, especially at higher volumes), mild headache (8%), dizziness (5%), and rare allergic reactions. The safety profile across 150+ trials is clean. No serious systemic adverse events at standard doses. The pig-derived nature means anyone with pork allergies should not use it.
Why is cerebrolysin not FDA-approved?
Cerebrolysin is a complex biological mixture, not a single molecule. FDA approval requires characterizing the exact active ingredient and mechanism, which is harder for a multi-peptide mixture than a single compound. It is not a safety issue. Over 40 countries have approved it. The US regulatory path for biological mixtures is simply more restrictive.
How do you inject cerebrolysin?
Cerebrolysin comes in pre-filled ampoules (1mL, 5mL, 10mL). No reconstitution needed. For IM injection: use a 22-25 gauge needle (thicker than typical peptide needles because of the volume). Inject in the gluteal muscle or deltoid. For volumes over 3mL, split across two injection sites. Inject slowly.
Evidence
Emerging evidence. Cerebrolysin is a mixture of brain-derived peptides and amino acids produced by enzymatic breakdown of pig brain protein. It has the most clinical data of any nootropic peptide: over 150 published trials for stroke, TBI, Alzheimer's, and vascular dementia. Approved in over 40 countries (not the US). The evidence is mixed, mostly positive for acute neurological injury, less clear for cognitive enhancement in healthy people.
Approval status: Approved in 40+ countries (EU, Asia, Latin America). Not FDA-approved.
References
Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci, 2018. PMID 29164397
Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke, 2016. PMID 26578657
Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol, 2006. PMID 16420397
Storage
Solution: Store at room temperature (15-25C). Protect from light. Do not freeze. Do not refrigerate.
Ampoule: Use immediately after opening. Do not store opened ampoules.
Needle: 22-25 gauge for IM injection (larger gauge than typical peptides due to volume)
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
This page is a community reference, not medical advice. Content reflects what users report, not clinical recommendations. Nothing here is approved for human use unless specifically noted. Always consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
